Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead

23 Aug 2008

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 18790076
DOI: 10.1016/j.biocel.2008.08.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epi-drugs to fight cancer: From chemistry to cancer treatment, the road aheadPMID 18790076Read ↗

Bringing science to cancer therapy.Semantic proximity Read ↗

Choosing anticancer drug targets in the postgenomic era.Semantic proximity Read ↗

Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunitiesSemantic proximity Read ↗

Achieving personalized cancer medicine: trials and tribulations.Semantic proximity Read ↗

Transitioning pharmacoperones to therapeutic use: In vivo proof-of-principle and design of high throughput screensSemantic proximity Read ↗

Development of PARP inhibitors: an unfinished story.Semantic proximity Read ↗

Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints.Semantic proximity Read ↗

PARP inhibitors coming of ageSemantic proximity Read ↗

Genomics and the second golden era of cancer drug developmentSemantic proximity Read ↗

Non-oncology drugs are a source of previously unappreciated anti-cancer activitySemantic proximity Read ↗

Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological TargetsSemantic proximity Read ↗

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.